Syndax Pharmaceuticals (SNDX) Net Cash Flow Growth (1y) (2016 - 2026)
Syndax Pharmaceuticals (SNDX) Net Cash Flow Growth (1y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,071.81 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,925.70 Bn | 1,925.64 Bn | - | - |
| 3 | Akari Therapeutics | 1,062.88 Bn | 1,062.88 Bn | - | - |
| 4 | BeOne Medicines | 469.09 Bn | 464.29 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 123.09 Bn | 115.84 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.32 Bn | 61.57 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 63.36 Bn | 63.36 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.71 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.69 Bn | 34.68 Bn | 959.66 Mn | 53.46% |
| 10 | Syndax Pharmaceuticals | 1.85 Bn | 1.50 Bn | 53.02 Mn | -4,385.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,385.56% |
| Dec 31, 2025 | -14.51% |
| Sep 30, 2025 | -70.42% |
| Jun 30, 2025 | -391.99% |
| Mar 31, 2025 | 99.95% |
| Dec 31, 2024 | -89.51% |
| Sep 30, 2024 | 1,113.69% |
| Jun 30, 2024 | -123.13% |
| Mar 31, 2024 | -973.57% |
| Dec 31, 2023 | 6,641.99% |
| Sep 30, 2023 | 94.42% |
| Jun 30, 2023 | 158.16% |
| Mar 31, 2023 | 49.27% |
| Dec 31, 2022 | -98.02% |
| Sep 30, 2022 | -1,540.51% |
| Jun 30, 2022 | -1,975.08% |
| Mar 31, 2022 | 34.73% |
| Dec 31, 2021 | 155.63% |
| Sep 30, 2021 | 23.57% |
| Jun 30, 2021 | -59.31% |